Testing for COVID-19: Increasing testing supply

On this page

What Canada is doing

Canada is mobilizing industry and providing support for research, market approval, manufacturing and access to medical supplies. We're working proactively with companies that are developing new and innovative testing technologies. We're also engaging with international regulators to share knowledge about new developments related to testing.

Increasing testing options

Health Canada reviews testing devices to assess their safety, effectiveness and quality before they're authorized for sale in Canada. For a test to be authorized by Health Canada, it must be submitted for review by the manufacturer. To date, Health Canada has authorized over 50 different COVID-19 tests. We also continue to expedite the review of COVID-19 tests, including new testing options.

Health Canada is currently prioritizing the review of:

Health Canada has received a number of antigen test applications that are under priority review. Antigen tests detect specific proteins on the surface of the virus and provide rapid results.

A small number of saliva tests have been submitted to Health Canada and are under priority review. Health Canada hasn't authorized any tests for use with saliva at this time.

Health Canada will expedite the review of any new testing technologies submitted by manufacturers, including at-home test kits (also known as "self-testing"). For at-home test kits, the manufacturer must provide data to show the test is safe and effective for Canadians to use without health care professional supervision.

In all cases, companies must provide evidence that the test is accurate and reliable before Health Canada will authorize it. Health Canada has provided guidance to manufacturers on the authorization requirements for different types of tests such as antibody tests and antigen tests.

Securing rapid tests

Public Services and Procurement Canada has purchased rapid tests on behalf of and at the direction of the Public Health Agency of Canada. This purchase ensures that the federal government can increase testing capacity with authorized, proven and effective technologies. Explore COVID-19 rapid test purchase agreements.

Rapid tests distributed in Canada

The Government of Canada has purchased millions of rapid tests to distribute across the country and add an extra layer of defence against the spread of the virus. Find out about our rapid test agreements and types of tests we have purchased.

The tables below show the number of COVID-19 rapid tests that have been shipped in provinces and territories as of January 14, 2022 (deployment and usage data as of December 10, 2021). The data for “tests deployed” show the quantities of rapid tests that have been distributed to their final point-of-care setting where they will be administered to patients. The data for “tests used” depict how many of those rapid tests have been administered.

There is a delay in the reporting on the deployment of rapid tests. This is due to the time when tests are:

The numbers listed are updated regularly.

Canada
Distribution of tests in Canada
Product name Tests shipped Tests shipped to PTs Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 6,611,544 5,642,272 2,415,804 1,127,684
Abbott Panbio 67,492,900 58,624,835 50,572,943 12,893,240
BD Veritor 12,256,290 10,492,710 9,442,593 1,126,113
Quidel Sofia 850,000 73,200 2,844 0
BTNX 58,073,200 57,954,460 5,765,475 150,640
Roche 1,750,000 559,925 0 0
Quidel QuickVue 9,238,275 2,002,450 287,375 3,906
Lucira 174,250 24,402 2,400 533
Switch Health 2,571,200 2,559,200 - -
Artron 1,458,730 1,208,730 - -
Trimedic 3,372,840 3,372,840 - -
CanAm 1,663,700 0 - -
Total 165,512,929 142,515,024 68,489,434 15,302,116
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Newfoundland and Labrador
Distribution of tests for Newfoundland and Labrador
Product name Testrs shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 91,432 86,208 10,571
Abbott Panbio 305,000 304,375 15,258
BD Veritor 0 0 0
BTNX 250,020 0 0
Roche 0 0 0
Quidel QuickVue 805,475 0 0
Lucira 0 0 0
Total 1,451,927 390,583 25,829
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Prince Edward Island
Distribution of tests for Prince Edward Island
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 620,208 no information provided 296,337
Abbott Panbio 196,000 50,800 50,800
BD Veritor 0 0 0
BTNX 200,000 63,260 18,000
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 5,000 0 0
Switch Health 160,000 - -
Total 1,181,208 114,060 365,137
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Nova Scotia
Distribution of tests for Nova Scotia
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 106,512 1,491 1,491
Abbott Panbio 5,631,625 1,510,248 884,874
BD Veritor 920,520 508,452 121,452
BTNX 2,919,440 132,000 132,000
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 15,000 0 0
Switch Health 395,200 - -
Total 9,988,297 2,152,191 1,139,817
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

New Brunswick
Distribution of tests for New Brunswick
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 111,040 13,268 1,126
Abbott Panbio 4,251,200 1,445,705 324,778
BD Veritor 0 0 0
BTNX 4,500,000 1,991,455 0
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 0 0 0
Total 8,862,240 3,450,428 325,904
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Quebec
Distribution of tests for Quebec
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 1,522,648 935,616 482,467
Abbott Panbio 8,463,750 5,657,619 28,636
BD Veritor 1,161,420 894,840 41,000
BTNX 19,729,280 0 0
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 1,802 0 0
Total 30,878,900 7,488,075 552,103
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Ontario
Distribution of tests for Ontario
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 1,338,432 549,975 108,329
Abbott Panbio 20,148,263 28,375,765 9,206,370
BD Veritor 4,364,220 3,867,805 366,930
Quidel Sofia 73,200 2,844 0
BTNX 11,324,940 1,252,060 0
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 0 0 0
Switch Health 1,872,000 no information provided no information reported
Artron 457,820 - -
Trimedic 3,372,840 - -
Total 42,951,715 34,048,449 9,681,629
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used and may also include tests purchased by the province.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date and may also include tests purchased by the province.

Return to footnote ** referrer

Manitoba
Distribution of tests for Manitoba
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 176,448 21,024 no information provided
Abbott Panbio 3,081,000 407,475 no information provided
BD Veritor 995,250 11,520 no information provided
BTNX 260,280 0 no information provided
Roche 300,325 0 no information provided
Quidel QuickVue 1,196,975 0 no information provided
Lucira 0 0 no information provided
Switch Health 132,000 no information provided no information provided
Total 6,142,278 440,019 no information provided
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Saskatchewan
Distribution of tests for Saskatchewan
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 348,416 235,848 no information provided
Abbott Panbio 6,224,775 3,510,575 no information provided
BD Veritor 1,642,500 1,479,150 no information provided
BTNX 8,180,870 2,287,675 no information provided
Roche 0 0 no information provided
Quidel QuickVue 0 0 no information provided
Lucira 0 0 no information provided
Total 16,396,561 7,513,248 no information provided
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

Data verification ongoing.

Return to footnote ** referrer

Alberta
Distribution of tests for Alberta
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 537,912 274,702 160,841
Abbott Panbio 6,694,772 4,325,034 1,247,082
BD Veritor 1,018,920 1,465,856 403,350
BTNX 10,542,470 39,025 640
Roche 30,000 0 0
Quidel QuickVue 0 0 0
Lucira 2,600 2,400 533
Total 18,826,624 6,107,017 1,812,446
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

British Columbia
Distribution of tests for British Columbia
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 644,760 88,488 27,553
Abbott Panbio 3,370,900 1,091,400 237,632
BD Veritor 389,880 81,210 60,834
BTNX 0 0 0
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 0 0 0
Artron 750,910 - -
Total 5,156,450 1,261,098 326,019
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Yukon
Distribution of tests for Yukon
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 23,648 no information provided no information provided
Abbott Panbio 30,000 no information provided no information provided
BD Veritor 0 0 0
BTNX 0 0 0
Roche 229,600 0 0
Quidel QuickVue 0 0 0
Lucira 0 0 0
Total 283,248 0 0
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Northwest Territories
Distribution of tests for Northwest Territories
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 93,480 40,656 20,040
Abbott Panbio 168,800 8,817 350
BD Veritor 0 0 0
BTNX 47,160 0 0
Roche 0 0 0
Quidel QuickVue 0 0 0
Lucira 0 0 0
Total 309,440 49,473 20,390
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Nunavut
Distribution of tests for Nunavut
Product name Tests shipped Tests deployedFootnote * Tests used (as reported)Footnote **
Abbott ID Now 27,336 5,424 no information provided
Abbott Panbio 58,800 14,400 no information provided
BD Veritor 0 0 no information provided
BTNX 0 0 no information provided
Roche 0 0 no information provided
Quidel QuickVue 0 0 no information provided
Lucira 0 0 no information provided
Total 86,136 19,824 no information provided
Footnote *

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote * referrer

Footnote **

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote ** referrer

Federal allocation
Distribution of tests for Federal OperationsFootnote *
Product name Tests shippedFootnote ** Tests deployedFootnote *** Tests used (as reported)Footnote ****
Abbott ID Now 280,136 280,136 19,909
Abbott Panbio 434,350 434,350 136,228
BD Veritor 11,600 11,600 363
Quidel Sofia 8,400 8,400 2,957
Lucira 1,034 1,034 0
Quidel QuickVue 325,000 325,000 82,771
GeneXpert 89,950 89,950 -
Total 876,379 876,379 242,228
Footnote *

The federal operations numbers include tests distributed to federal government departments such as: Department of National Defence (DND), Correctional Services Canada (CSC), the Public Health Agency of Canada (PHAC), as well as Northern, remote and Indigenous communities.

Return to footnote * referrer

Footnote **

The tests shipped and deployed information includes data as of January 14, 2022. Usage data is current as of December 10, 2021.

Return to footnote ** referrer

Footnote ***

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote *** referrer

Footnote ****

The tests used information shows data that has been reported to Health Canada to date.

Return to footnote **** referrer

Direct to organizations for workplace screeningFootnote *
Product name Tests available Tests deployedFootnote ** Tests used (as reported)Footnote ***
Abbott ID Now 0 0 0
Abbott Panbio 4,578,625 3,572,405 916,263
BD Veritor 1,133,760 1,133,760 195,568
BTNX - - 1,418
Quidel Sofia 0 0 0
Quidel QuickVue 287,375 287,375 42,227
Total 5,999,760 4,993,540 1,155,476
Footnote *

Federal distribution numbers include tests shipped to businesses, non-profit organizations, crown corporations, and distribution partners such as pharmacies and the Canadian Red Cross.

Return to footnote * referrer

Footnote **

The tests deployed information shows the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used.

Return to footnote ** referrer

Footnote ***

The tests used information shows data that has been reported to Health Canada as of January 14, 2022. Tests available and deployed data is current as of December 10, 2021.

Return to footnote *** referrer

Supporting provincial and territorial COVID-19 testing capacity

The federal government is providing $4.28 billion to the provinces and territories. This money is to help them conduct testing, perform contact tracing and share public health data that will help fight the pandemic. The goal is to ensure they have the capacity to test up to 200,000 people each day, nationwide.

Canada is also providing funding and support to improve and modernize data management across Canada. This support is to help all levels of government coordinate their efforts to contain the virus.

The table below shows the current capacity for each province and territory compared to the capacity target agreed to under the Safe Restart Agreement.

The national capacity target of about 200,000 tests each day is based on modelling. This modelling exercise indicates this capacity is enough to meet the expected demand for testing.

Provincial and territorial COVID-19 testing capacity

Testing capacity reported as of November 30, 2021.

Please consult the Coronavirus disease 2019 (COVID-19): Epidemiology update for daily and weekly updates on the average number of people tested.

In circumstances where capacity was not reported, the previous week's capacity was indicated (see *).

Newfoundland and Labrador: Target 2,500 - 3,000
COVID-19 testing capacity for Newfoundland and Labrador (Target 2,500 - 3,000Footnote***)
Date Projected daily maximum testing capacity
2020-09-03 1,450
2020-09-10 1,450
2020-09-17 1,450
2020-09-24 1,450
2020-10-01 1,450
2020-10-08 1,450
2020-10-15 1,450
2020-10-22 1,450
2020-10-29 1,450
2020-11-03 1,450
2020-11-10 1,450
2020-11-17 1,450
2020-11-24 1,450
2020-12-01 1,450
2020-12-08 1,450
2020-12-15 1,450
2020-12-22 1,450
2020-12-29 1,450
2021-01-05 1,450
2021-01-12 1,450
2021-01-19 1,450
2021-01-26 1,450
2021-02-02 1,450
2021-02-09 1,700
2021-02-16 1,700Footnote *
2021-02-23 1,700
2021-03-02 1,700
2021-03-09 1,700
2021-03-16 1,700
2021-03-23 2,100
2021-03-29 2,100
2021-04-06 2,100
2021-04-12 2,500
2021-04-19 2,500
2021-04-26 2,500
2021-05-03 2,700
2021-05-10 2,700
2021-05-17 2,700
2021-05-24 2,700
2021-05-31 2,700
2021-06-30 2,700
2021-07-31 2,700
2021-08-31 2,700
2021-09-30 2,700
2021-10-31 2,700
2021-11-30 2,700
Footnote ***

Target updated October 6 at the request of Newfoundland and Labrador

Return to footnote*** referrer

Prince Edward Island: Target 835
COVID-19 testing capacity for Prince Edward Island (Target 835)
Date Projected daily maximum testing capacity
2020-09-03 350
2020-09-10 430
2020-09-17 350
2020-09-24 350
2020-10-01 400
2020-10-08 400
2020-10-15 400 (800Footnote**)
2020-10-22 400 (800Footnote**)
2020-10-29 400 (800Footnote**)
2020-11-03 400 (800Footnote**)
2020-11-10 400 (800Footnote**)
2020-11-17 400 (800Footnote**)
2020-11-24 400 (800Footnote**)
2020-12-01 400 (800Footnote**)
2020-12-08 400Footnote* (800Footnote**)
2020-12-15 400 (800Footnote**)
2020-12-22 400
2020-12-29 400
2021-01-05 600
2021-01-12 600
2021-01-19 600
2021-01-26 600
2021-02-02 700
2021-02-09 850
2021-02-16 850
2021-02-23 850
2021-03-02 850
2021-03-09 850
2021-03-16 850
2021-03-23 850
2021-03-29 850
2021-04-06 850
2021-04-12 850
2021-04-19 850
2021-04-26 850
2021-05-03 850
2021-05-10 850
2021-05-17 850
2021-05-24 850
2021-05-31 850
2021-06-30 850
2021-07-31 850
2021-08-31 850
2021-09-30 850
2021-10-31 850
2021-11-30 850
Footnote **

Revised to include the surge testing capacity available on a temporary basis.

Return to footnote** referrer

Nova Scotia: Target 2,500
COVID-19 testing capacity for Nova Scotia (Target 2,500)
Date Projected daily maximum testing capacity
2020-09-03 1,500
2020-09-10 1,500
2020-09-17 1,500
2020-09-24 1,500
2020-10-01 1,500
2020-10-08 1,500
2020-10-15 1,500
2020-10-22 1,500
2020-10-29 1,500
2020-11-03 1,500
2020-11-10 1,500
2020-11-17 1,500
2020-11-24 2,500
2020-12-01 2,500
2020-12-08 2,500
2020-12-15 2,500
2020-12-22 2,500
2020-12-29 2,500
2021-01-05 2,500
2021-01-12 2,500
2021-01-19 2,500
2021-01-26 2,500
2021-02-02 2,500
2021-02-09 2,500
2021-02-16 2,500
2021-02-23 2,500
2021-03-02 2,500
2021-03-09 2,500
2021-03-16 2,500
2021-03-23 2,500
2021-03-29 2,500
2021-04-06 2,500
2021-04-12 2,500
2021-04-19 2,500
2021-04-26 2,500
2021-05-03 10,000
2021-05-10 10,000
2021-05-17 10,000
2021-05-24 10,000
2021-05-31 10,000
2021-06-30 10,000
2021-07-31 10,000
2021-08-31 10,000
2021-09-30 10,000
2021-10-31 10,000
2021-11-30 10,000
New Brunswick: Target 2,500 - 3,000
COVID-19 testing capacity for New Brunswick (Target 2,500 - 3,000)
Date Projected daily maximum testing capacity
2020-09-03 1,500
2020-09-10 1,500
2020-09-17 1,500
2020-09-24 1,500
2020-10-01 1,500
2020-10-08 1,500
2020-10-15 1,500
2020-10-22 1,500
2020-10-29 2,000
2020-11-03 2,000
2020-11-10 2,000
2020-11-17 2,000
2020-11-24 2,000Footnote*
2020-12-01 2,000
2020-12-08 2,000Footnote*
2020-12-15 2,500
2020-12-22 2,500
2020-12-29 2,500
2021-01-05 2,500
2021-01-12 2,000
2021-01-19 2,000
2021-01-26 2,000
2021-02-02 2,000
2021-02-09 3,000
2021-02-16 3,000
2021-02-23 3,000
2021-03-02 3,000
2021-03-09 3,000
2021-03-16 3,000
2021-03-23 3,000
2021-03-29 3,000
2021-04-06 3,000
2021-04-12 3,000
2021-04-19 3,000
2021-04-26 3,000
2021-05-03 3,000
2021-05-10 3,000
2021-05-17 3,000
2021-05-24 3,000
2021-05-31 3,000
2021-06-30 3,000
2021-07-31 3,000
2021-08-31 3,000
2021-09-30 3,000
2021-10-31 3,000
2021-11-30 3,000
Quebec: Target 35,000
COVID-19 testing capacity for Quebec (Target 35,000)
Date Projected daily maximum testing capacity
2020-09-03 20,000
2020-09-10 20,000
2020-09-17 20,000
2020-09-24 20,000
2020-10-01 20,000
2020-10-08 20,000
2020-10-15 20,000
2020-10-22 20,000
2020-10-29 20,000
2020-11-03 20,000
2020-11-10 20,000
2020-11-17 20,000
2020-11-24 20,000
2020-12-01 20,000
2020-12-08 35,199
2020-12-15 37,142
2020-12-22 38,846
2020-12-29 40,196
2021-01-05 37,972
2021-01-12 39,127
2021-01-19 36,929
2021-01-26 40,084
2021-02-02 40,977
2021-02-09 42,386
2021-02-16 39,497
2021-02-23 43,987
2021-03-02 41,386
2021-03-09 42,758
2021-03-16 42,427
2021-03-23 43,382
2021-03-29 44,037
2021-04-06 46,392
2021-04-12 48,221
2021-04-19 47,959
2021-04-26 47,659
2021-05-03 47,771
2021-05-10 48,098
2021-05-17 48,471
2021-05-24 46,104
2021-05-31 46,338
2021-06-30 46,048
2021-07-31 46,048
2021-08-31 47,653
2021-09-30 47,653
2021-10-31 46,915
2021-11-30 46,915
Ontario: Target 78,000
COVID-19 testing capacity for Ontario (Target 78,000)
Date Projected daily maximum testing capacity
2020-09-03 35,108
2020-09-10 39,690
2020-09-17 42,434
2020-09-24 42,816
2020-10-01 42,942
2020-10-08 50,692
2020-10-15 51,397
2020-10-22 64,340
2020-10-29 67,094
2020-11-03 71,564
2020-11-10 78,964
2020-11-17 80,856
2020-11-24 81,630
2020-12-01 81,630
2020-12-08 74,008
2020-12-15 77,333
2020-12-22 77,333
2020-12-29 77,581
2021-01-05 79,821
2021-01-12 120,608
2021-01-19 120,608
2021-01-26 120,608
2021-02-02 116,000
2021-02-09 116,000
2021-02-16 116,000
2021-02-23 116,000
2021-03-02 116,000
2021-03-09 117,800
2021-03-16 118,400
2021-03-23 118,400
2021-03-29 118,400
2021-04-06 120,200
2021-04-12 120,200
2021-04-19 120,200
2021-04-26 120,200
2021-05-03 120,200
2021-05-10 124,700
2021-05-17 124,700
2021-05-24 124,700
2021-05-31 124,700
2021-06-30 124,700
2021-07-31 124,700
2021-08-31 124,700
2021-09-30 124,700
2021-10-31 124,700
2021-11-30 124,700
Manitoba: Target 3,000
COVID-19 testing capacity for Manitoba (Target 3,000)
Date Projected daily maximum testing capacity
2020-09-03 3,000
2020-09-10 3,000
2020-09-17 3,000
2020-09-24 3,000
2020-10-01 3,000
2020-10-08 3,000
2020-10-15 3,000
2020-10-22 3,000
2020-10-29 3,000
2020-11-03 3,000
2020-11-10 3,000
2020-11-17 3,000
2020-11-24 3,000Footnote*
2020-12-01 2,841
2020-12-08 2,841Footnote*
2020-12-15 2,841Footnote*
2020-12-22 3,500
2020-12-29 3,500
2021-01-05 3,500
2021-01-12 3,500
2021-01-19 3,500
2021-01-26 3,500
2021-02-02 3,500
2021-02-09 3,500Footnote*
2021-02-16 3,500
2021-02-23 3,500
2021-03-02 3,500
2021-03-09 3,500Footnote*
2021-03-16 3,500
2021-03-23Footnote* 3,500
2021-03-29 3,500
2021-04-06 3,500Footnote*
2021-04-12 3,500Footnote*
2021-04-19 3,500Footnote*
2021-04-26 3,500Footnote*
2021-05-03 3,500Footnote*
2021-05-10 3,500Footnote*
2021-05-17 3,500Footnote*
2021-05-24 3,500Footnote*
2021-05-31 3,500Footnote*
2021-06-30 3,500Footnote*
2021-07-31 3,500Footnote*
2021-08-31 4,000
2021-09-30 4,000
2021-10-31 4,000
2021-11-30 4,000
Saskatchewan: Target 4,000
COVID-19 testing capacity for Saskatchewan (Target 4,000)
Date Projected daily maximum testing capacity
2020-09-03 1,800
2020-09-10 1,800
2020-09-17 1,800
2020-09-24 1,800
2020-10-01 1,800
2020-10-08 1,800
2020-10-15 1,800
2020-10-22 1,800
2020-10-29 1,800
2020-11-03 1,800
2020-11-10 2,100
2020-11-17 2,700
2020-11-24 2,700
2020-12-01 3,330
2020-12-08 3,450
2020-12-15 3,450
2020-12-22 3,450
2020-12-29 3,450
2021-01-05 3,846
2021-01-12 3,846
2021-01-19 3,846
2021-01-26 3,846
2021-02-02 3,846
2021-02-09 3,846Footnote*
2021-02-16 3,846Footnote*
2021-02-23 3,846
2021-03-02 3,846
2021-03-09 3,846
2021-03-16 4,000
2021-03-23 4,500
2021-03-29 4,500
2021-04-06 4,500
2021-04-12 4,500
2021-04-19 4,500
2021-04-26 4,500
2021-05-03 4,500
2021-05-10 4,500
2021-05-17 4,500
2021-05-24 4,500
2021-05-31 4,500
2021-07-31 4,500
2021-08-31 4,500
2021-09-30 3,000
2021-10-31 3,000
2021-11-30 3,000
Alberta: Target 22,000
COVID-19 testing capacity for Alberta (Target 22,000)
Date Projected daily maximum testing capacity
2020-09-03 12,000
2020-09-10 12,000
2020-09-17 12,000
2020-09-24 12,000
2020-10-01 15,500
2020-10-08 22,000
2020-10-15 22,000
2020-10-22 22,000
2020-10-29 22,000
2020-11-03 22,000
2020-11-10 22,000
2020-11-17 22,000
2020-11-24 22,000
2020-12-01 22,000
2020-12-08 22,000Footnote*
2020-12-15 22,000
2020-12-22 22,000
2020-12-29 22,000
2021-01-05 22,000
2021-01-12 22,000
2021-01-19 22,000
2021-01-26 22,000
2021-02-02 22,000
2021-02-09 22,000
2021-02-16 22,000
2021-02-23 22,000
2021-03-02 22,000
2021-03-09 22,000
2021-03-16 22,000
2021-03-23 22,000
2021-03-29 22,000
2021-04-06 22,000
2021-04-12 22,000
2021-04-19 22,000
2021-04-26 22,000
2021-05-03 22,000
2021-05-10 22,000
2021-05-17 22,000
2021-05-24 22,000
2021-05-31 22,000
2021-06-30 22,000
2021-07-31 22,000
2021-08-31 22,000
2021-09-30 22,000
2021-11-30 22,000
British Columbia: Target 20,000
COVID-19 testing capacity for British Columbia (Target 20,000)
Date Projected daily maximum testing capacity
2020-09-03 7,842
2020-09-10 8,581
2020-09-17 7,996
2020-09-24 9,633
2020-10-01 9,714
2020-10-08 10,506
2020-10-15 10,586
2020-10-22 12,840
2020-10-29 13,685
2020-11-03 17,033
2020-11-10 17,333
2020-11-17 18,733
2020-11-24 18,733
2020-12-01 18,733
2020-12-08 18,945
2020-12-15 18,945
2020-12-22 18,945
2020-12-29 18,945
2021-01-05 19,439
2021-01-12 19,439
2021-01-19 19,817
2021-01-26 19,817
2021-02-02 19,817
2021-02-09 19,817
2021-02-16 19,817
2021-02-23 20,617
2021-03-02 20,617
2021-03-09 20,617
2021-03-16 20,617
2021-03-23 21,332
2021-03-29 21,332
2021-04-06 19,932
2021-04-12 18,932
2021-04-19 20,132
2021-04-26 20,132
2021-05-03 20,132
2021-05-10 20,132
2021-05-17 20,132
2021-05-24 20,132
2021-05-31 20,132
2021-06-30 20,132
2021-07-31 20,132
2021-08-31 20,132
2021-09-30 19,628
2021-10-31 19,628
2021-11-30 19,628
Yukon: Target 160
COVID-19 testing capacity for Yukon (Target 160)
Date Projected daily maximum testing capacity
2020-09-03 n/a
2020-09-10 n/a
2020-09-17 n/a
2020-09-24 n/a
2020-10-01 150
2020-10-08 150
2020-10-15 150
2020-10-22 150
2020-10-29 150
2020-11-03 150
2020-11-10 150
2020-11-17 150
2020-11-24 150
2020-12-01 150Footnote*
2020-12-08 150Footnote*
2020-12-15 150
2020-12-22 150
2020-12-22 150
2020-12-29 150
2021-01-05 150
2021-01-12 150
2021-01-19 150
2021-01-26 150Footnote*
2021-02-02 150Footnote*
2021-02-09 150
2021-02-16 150Footnote*
2021-02-23 150Footnote*
2021-03-02 150
2021-03-09 150Footnote*
2021-03-16 150Footnote*
2021-03-23 150
2021-03-29 150
2021-04-06 150
2021-04-12 150
2021-04-19 150
2021-04-26 150
2021-05-03 150
2021-05-10 150
2021-05-17 150
2021-05-24 150
2021-05-31 150
2021-06-30 150
2021-07-31 150
2021-08-31 150
2021-09-30 150
2021-10-31 150
2021-11-30 150
Northwest Territories: Target 225
COVID-19 testing capacity for Northwest Territories (Target 225)
Date Projected daily maximum testing capacity
2020-09-03 n/a
2020-09-10 n/a
2020-09-17 n/a
2020-09-24 n/a
2020-10-01 48
2020-10-08 48
2020-10-15 48
2020-10-22 48
2020-10-29 75
2020-11-03 75
2020-11-10 75
2020-11-17 75
2020-11-24 75
2020-12-01 75Footnote*
2020-12-08 75Footnote*
2020-12-15 75Footnote*
2020-12-22 75
2020-12-29 75
2021-01-05 75
2021-01-12 75
2021-01-19 75
2021-01-26 75*
2021-02-02 110
2021-02-09 110
2021-02-16 110
2021-02-23 110
2021-03-02 110
2021-03-09 110
2021-03-16 110
2021-03-23 110
2021-03-29 110
2021-04-06 110
2021-04-12 100
2021-04-19 110
2021-04-26 110
2021-05-03 110
2021-05-10 110
2021-05-17 110
2021-05-24 110
2021-05-31 110
2021-06-30 110
2021-07-31 110
2021-08-31 110
2021-09-30 110
2021-10-31 110
2021-11-30 110
Nunavut: Target n/a
COVID-19 testing capacity for Nunavut (Target n/a)
Date Projected daily maximum testing capacity
2020-09-03 n/a
2020-09-10 n/a
2020-09-17 n/a
2020-09-24 n/a
2020-10-01 n/a
2020-10-08 n/a
2020-10-15 80
2020-10-22 80
2020-10-29 80
2020-11-03 100
2020-11-10 200
2020-11-17 200
2020-11-24 200
2020-12-01 200
2020-12-08 200
2020-12-15 250
2020-12-22 250
2020-12-29 250
2021-01-05 250
2021-01-12 250
2021-01-19 300
2021-01-26 300
2021-02-02 300
2021-02-09 300
2021-02-16 300
2021-02-23 300
2021-03-02 300
2021-03-09 300
2021-03-16 300
2021-03-23 300
2021-03-29 300
2021-04-06 300
2021-04-12 300
2021-04-19 300
2021-04-26 300
2021-05-03 300
2021-05-10 300
2021-05-17 300
2021-05-24 300
2021-05-31 300
2021-06-30 300
2021-07-31 300
2021-08-31 300
2021-09-30 300
2021-10-31 300
2021-11-30 300
Canada: Target 170,720 - 171,220
COVID-19 testing capacity for Canada (Target 170,720 - 171,220)
Date Projected daily maximum testing capacity
2020-09-03 84,550
2020-09-10 89,951
2020-09-17 92,030
2020-09-24 94,049
2020-10-01 82,504
2020-10-08 113,046
2020-10-15 113,911
2020-10-22 128,838
2020-10-29 132,234
2020-11-03 141,072
2020-11-10 149,172
2020-11-17 153,064
2020-11-24 154,838
2020-12-01 155,309
2020-12-08 163,218
2020-12-15 169,036
2020-12-22 171,399
2020-12-29 172,997
2021-01-05 174,103
2021-01-12 215,545
2021-01-19 213,775
2021-01-26 216,930
2021-02-02 213,350
2021-02-09 216,159
2021-02-16 213,270
2021-02-23 218,560
2021-03-02 215,959
2021-03-09 219,131
2021-03-16 219,599
2021-03-23 222,124
2021-03-29 222,779
2021-04-06 225,534
2021-04-12 226,763
2021-04-19 227,701
2021-04-26 227,401
2021-05-03 235,213
2021-05-10 240,040
2021-05-17 240,413
2021-05-24 238,046
2021-05-31 238,280
2021-06-30 237,990
2021-07-31 237,990
2021-08-31 240,095
2021-09-30 238,091
2021-10-31 237,353
2021-11-30 237,353

Related links

Did you find what you were looking for?

What was wrong?

You will not receive a reply. Telephone numbers and email addresses will be removed.
Maximum 300 characters

Thank you for your feedback

Date modified: